Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection
Jiahe Chen, Cynthia L. Gong, Matthew M. Hitchcock, Marisa Holubar, Stanley C. Deresinski, Joel W. Hay
Topics & Concepts
FidaxomicinVancomycinMedicineClostridioidesCost effectivenessInternal medicineSurgeryStaphylococcus aureusRisk analysis (engineering)GeneticsBiologyBacteriaClostridium difficile and Clostridium perfringens researchHelicobacter pylori-related gastroenterology studiesNosocomial Infections in ICU